,Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes
0,prerank,KEGG_2021_Human__Ribosome,-0.8466372303791923,-3.374981253600485,0.0,0.0,0.0,71/88,10.94%,RPLP1;RPS24;RPS26;RPL34;RPS29;RPL30;RPL27A;RPS20;RPL23A;RPLP2;RPL11;RPL17;FAU;RPL6;RPL32;RPS9;RPL37A;RPS27A;RPL23;RPS18;RPL38;RPL14;RPL27;RPL22;RPL12;RPL35;RPL29;RPL39;RPL41;RPL21;RPS12;RPS10;UBA52;RPS15;RPS23;RPLP0;RPL36A;RPL10A;RPS11;RPS14;RPS7;RPL37;RPL9;RPS13;RPL31;RPS3A;RPL35A;MRPL20;RPL36;RPS21;RPS15A;RPS8;RPS27;RPL26;RPL10;RPS3;RPL24;RPS4X;RPL13;RPL5;RPS6;MRPS6;RPL3;RPS25;RPL19;RPL28;RPSA;RPL7;RPL18;RPL7A;RPS19
1,prerank,KEGG_2021_Human__Coronavirus disease,-0.680218974022484,-2.8915004974437304,0.0,0.0,0.0,72/138,10.94%,CFD;RPLP1;RPS24;C5AR1;RPS26;RPL34;RPS29;RPL30;RPL27A;RPS20;NLRP3;RPL23A;RPLP2;RPL11;RPL17;FAU;RPL6;RPL32;RPS9;RPL37A;RPS27A;RPL23;RPS18;RPL38;RPL14;RPL27;RPL22;RPL12;RPL35;RPL29;RPL39;RPL41;RPL21;RPS12;RPS10;UBA52;RPS15;RPS23;RPLP0;RPL36A;RPL10A;RPS11;RPS14;RPS7;RPL37;RPL9;RPS13;RPL31;RPS3A;RPL35A;RPL36;RPS21;RPS15A;RPS8;RPS27;RPL26;RPL10;RPS3;RPL24;RPS4X;RPL13;RPL5;RPS6;RPL3;RPS25;RPL19;RPL28;RPSA;RPL7;RPL18;RPL7A;RPS19
2,prerank,KEGG_2021_Human__Lysosome,0.7297460855954524,2.42617454416706,0.0,0.0,0.0,28/51,13.96%,CTSA;LAMP1;CTSD;HEXB;GBA;CD164;TPP1;CD63;ASAH1;CTSC;SLC11A2;GNPTG;ATP6AP1;M6PR;CLTC;NPC1;ATP6V1H;NPC2;HEXA;MCOLN1;IGF2R;PSAP;ATP6V0A1;TCIRG1;NEU1;GNS;AP3S1;MANBA
3,prerank,KEGG_2021_Human__Viral myocarditis,-0.6802194048156176,-2.141816069363157,0.0,0.0,0.0,10/27,14.15%,HLA-DPB1;HLA-DRB5;HLA-DPA1;CD55;HLA-DMA;HLA-DRA;HLA-DRB1;ABL2;HLA-DQA1;CYCS
4,prerank,KEGG_2021_Human__Vibrio cholerae infection,0.7232447570013523,2.0533993138984297,0.0,0.003207984316521119,0.006,10/23,11.16%,ADCY3;ATP6V1B2;ATP6V1E1;ATP6V1D;ATP6V1C1;ATP6V0E1;ATP6AP1;ATP6V1H;ATP6V0A1;TCIRG1
5,prerank,KEGG_2021_Human__Parkinson disease,-0.49974203274324913,-2.0369497694658443,0.0,0.0006738051710629408,0.003,48/102,24.65%,DUSP1;NDUFB2;COX6C;SLC25A5;RPS27A;NDUFA11;ERN1;UQCRB;NDUFA4;UBA52;TUBA1A;UQCRQ;UQCRH;GNAI2;COX4I1;COX8A;SLC25A6;COX7C;TUBA4A;HSPA5;NDUFA13;NDUFB7;NDUFA1;TUBA1B;PRKACA;NDUFB4;COX6A1;CYCS;COX7B;PSMD13;NDUFB11;VDAC1;NDUFS5;COX5B;NDUFB6;NDUFB3;XBP1;PSMB6;COX5A;DDIT3;CALM2;PSMB7;NDUFC1;UQCR10;GNAI3;COX7A2;NDUFA6;SDHB
6,prerank,MSigDB_Hallmark_2020__KRAS Signaling Up,0.568600012911627,1.9489284899022536,0.0,0.009267510247727677,0.021,10/54,6.45%,MAFB;C3AR1;SLPI;IL2RG;ALDH1A2;CLEC4A;SPP1;FCER1G;AVL9;ADAM17
7,prerank,MSigDB_Hallmark_2020__Myc Targets V1,-0.48092874798022983,-1.9241515150005393,0.0,0.006468529642204231,0.033,31/91,16.23%,SRSF2;RPL34;RPL6;RPL14;RPL22;HNRNPA1;RPS10;RPLP0;RAN;SLC25A3;U2AF1;RPS3;SNRPD2;TFDP1;SRSF3;RPS6;NAP1L1;RPL18;PABPC1;EEF1B2;HNRNPD;PRDX3;EIF4A1;LSM7;RPS2;SNRPD3;PA2G4;PPIA;XRCC6;SYNCRIP;VDAC1
8,prerank,KEGG_2021_Human__Spliceosome,-0.5114833426758535,-1.9100269072738145,0.0,0.006438582745712545,0.039,28/58,29.21%,SRSF2;SRSF5;LSM3;MAGOH;HNRNPA1;SRSF9;DDX5;U2AF1;SNRPD2;SRSF3;FUS;SNRPE;PRPF6;DDX46;LSM7;SNRPD3;RBM8A;CDC5L;SNRNP70;TRA2B;SF3A1;HNRNPM;CWC15;RBM22;SNRPB;SNRPG;ZMAT2;SF3B5
9,prerank,KEGG_2021_Human__Systemic lupus erythematosus,-0.6663975484336938,-1.9005327821133662,0.0022675736961451248,0.00641719210536134,0.045,12/18,18.36%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1;HLA-DQA1;SNRPD3;ACTN4;HLA-DQB1;ACTN1;FCGR3B
10,prerank,KEGG_2021_Human__Allograft rejection,-0.6957610679675151,-1.8825609927565132,0.0,0.007299556019848525,0.056,6/15,5.72%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1
11,prerank,KEGG_2021_Human__Graft-versus-host disease,-0.6579156772631181,-1.8426089319169672,0.002242152466367713,0.011279997678535155,0.091,6/17,5.72%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1
12,prerank,KEGG_2021_Human__Cardiac muscle contraction,-0.5932355643291154,-1.8387473831088685,0.002386634844868735,0.010511360668581875,0.094,16/24,23.84%,COX6C;UQCRB;UQCRQ;ATP1B1;UQCRH;COX4I1;COX8A;COX7C;ATP1B3;COX6A1;COX7B;COX5B;ATP2A3;COX5A;UQCR10;COX7A2
13,prerank,KEGG_2021_Human__Huntington disease,-0.44572288474700744,-1.837121811797159,0.0,0.009637455780051759,0.095,53/109,26.86%,NDUFB2;COX6C;SLC25A5;CLTB;DCTN3;NDUFA11;ERN1;UQCRB;NDUFA4;TUBA1A;UQCRQ;UQCRH;COX4I1;COX8A;SLC25A6;COX7C;AP2S1;TUBA4A;NDUFA13;NDUFB7;NDUFA1;GPX1;TUBA1B;RB1CC1;NDUFB4;COX6A1;CYCS;COX7B;PSMD13;POLR2F;NDUFB11;POLR2I;VDAC1;NDUFS5;COX5B;NDUFB6;NDUFB3;AP2M1;ATG2A;PSMB6;COX5A;PSMB7;NDUFC1;UQCR10;COX7A2;NDUFA6;SDHB;POLR2L;NDUFS6;POLR2K;PSMB1;CREB5;NDUFA2
14,prerank,KEGG_2021_Human__Type I diabetes mellitus,-0.6427952682813282,-1.8337764901833875,0.0044943820224719105,0.009058936188735092,0.097,6/19,5.72%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1
15,prerank,MSigDB_Hallmark_2020__Interferon Alpha Response,0.5149697293984323,1.8149093820027178,0.0,0.04517911245767243,0.12,25/68,21.67%,GBP4;TAP1;PARP14;IRF2;CSF1;NCOA7;IFI30;TMEM140;TRIM21;IFIH1;CCRL2;EPSTI1;DDX60;TRAFD1;SAMD9L;RIPK2;PARP9;OGFR;STAT2;ADAR;CD47;PLSCR1;CMPK2;IFI35;IFIT2
16,prerank,KEGG_2021_Human__Non-alcoholic fatty liver disease,-0.45723418012220896,-1.778888588663936,0.0,0.01693151455491492,0.185,45/79,31.57%,NDUFB2;COX6C;NDUFA11;ERN1;UQCRB;NDUFA4;UQCRQ;UQCRH;COX4I1;COX8A;COX7C;NDUFA13;NDUFB7;NDUFA1;FOS;NDUFB4;COX6A1;CYCS;COX7B;NDUFB11;PIK3CD;NDUFS5;COX5B;NDUFB6;IL1B;NDUFB3;XBP1;COX5A;DDIT3;NDUFC1;UQCR10;COX7A2;NDUFA6;SDHB;NDUFS6;IL1A;SREBF1;NDUFA2;NDUFB10;IRS2;NDUFB1;NDUFAB1;COX6B1;NDUFC2;RXRA
17,prerank,KEGG_2021_Human__Staphylococcus aureus infection,-0.5565243255809971,-1.7757252829368886,0.007352941176470588,0.01642801178972503,0.194,9/28,8.21%,HLA-DPB1;HLA-DRB5;HLA-DPA1;CFD;C5AR1;HLA-DMA;HLA-DRA;HLA-DRB1;CAMP
18,prerank,KEGG_2021_Human__Human papillomavirus infection,0.47487871475741206,1.7720846245216602,0.0,0.06031010515059704,0.194,25/96,17.04%,ATP6V1B2;ATP6V1E1;PTGER4;ATP6V1D;ATP6V1C1;MAML2;SPP1;HES1;ATP6V0E1;MDM2;CREB1;ATP6AP1;TRAF3;ATP6V1H;UBR4;STAT1;FAS;ATP6V0A1;TCIRG1;RHEB;PIK3CA;NOTCH2;PSEN1;STAT2;TBK1
19,prerank,KEGG_2021_Human__mTOR signaling pathway,0.5252650351754573,1.7620744967188164,0.0016420361247947454,0.05792193904829799,0.222,11/53,8.33%,ATP6V1B2;ATP6V1E1;RRAGD;FLCN;SLC3A2;ATP6V1D;ATP6V1C1;RRAGC;ATP6V1H;LAMTOR3;FNIP1
20,prerank,KEGG_2021_Human__Synaptic vesicle cycle,0.6190906698655071,1.749245492569448,0.0,0.056674389591873105,0.251,9/23,11.16%,ATP6V1B2;ATP6V1E1;ATP6V1D;ATP6V1C1;ATP6V0E1;CLTC;ATP6V1H;ATP6V0A1;TCIRG1
21,prerank,KEGG_2021_Human__Amyotrophic lateral sclerosis,-0.40544136723105606,-1.7259888258101053,0.0,0.026413162705667275,0.285,47/129,20.47%,NDUFB2;COX6C;GABARAPL1;DCTN3;NDUFA11;ERN1;HNRNPA1;UQCRB;NDUFA4;CHCHD10;TUBA1A;UQCRQ;MAP2K3;UQCRH;COX4I1;COX8A;SRSF3;COX7C;TUBA4A;HSPA5;NDUFA13;FUS;NDUFB7;NDUFA1;GPX1;TUBA1B;RB1CC1;TPR;NDUFB4;COX6A1;CYCS;COX7B;MATR3;PSMD13;RAB8A;NDUFB11;VDAC1;NDUFS5;COX5B;NDUFB6;NDUFB3;XBP1;ATG2A;PSMB6;COX5A;NUP98;DDIT3
22,prerank,KEGG_2021_Human__Neuroactive ligand-receptor interaction,0.6174863671803033,1.6678908122947755,0.014285714285714285,0.12283906612012119,0.463,9/18,15.79%,C3AR1;PTGER4;PTAFR;P2RY14;EDN1;LEP;NR3C1;P2RX4;TSPO
23,prerank,KEGG_2021_Human__Epithelial cell signaling in Helicobacter pylori infection,0.5374490400615668,1.660452008885809,0.001763668430335097,0.11750727737182916,0.481,12/36,16.04%,ATP6V1B2;ATP6V1E1;ATP6V1D;ATP6V1C1;ATP6V0E1;ATP6AP1;ATP6V1H;ADAM17;ATP6V0A1;TCIRG1;ADAM10;JUN
24,prerank,KEGG_2021_Human__Prion disease,-0.3958953118479349,-1.6273768844238272,0.0,0.05890180203708541,0.529,49/111,27.01%,NDUFB2;COX6C;SLC25A5;NDUFA11;UQCRB;NDUFA4;TUBA1A;UQCRQ;UQCRH;COX4I1;COX8A;SLC25A6;COX7C;TUBA4A;HSPA5;NDUFA13;NDUFB7;NDUFA1;TUBA1B;PRKACA;NDUFB4;COX6A1;CYCS;COX7B;PSMD13;NDUFB11;NOTCH1;VDAC1;PIK3CD;NDUFS5;COX5B;NDUFB6;IL1B;NDUFB3;PSMB6;COX5A;DDIT3;PSMB7;NDUFC1;UQCR10;COX7A2;NDUFA6;SDHB;NDUFS6;IL1A;PSMB1;CREB5;NDUFA2;PPP3CA
25,prerank,MSigDB_Hallmark_2020__E2F Targets,-0.5000577230592692,-1.6089769392057263,0.018867924528301886,0.06436821163565976,0.57,16/30,26.98%,SRSF2;RAN;PRKDC;UBE2S;NAP1L1;PDS5B;HNRNPD;PA2G4;XRCC6;SYNCRIP;NAA38;TRA2B;ANP32E;SNRPB;LMNB1;HMGB2
26,prerank,KEGG_2021_Human__Alzheimer disease,-0.37734235235304586,-1.605466147039204,0.0,0.06268883665592989,0.58,56/130,27.01%,NDUFB2;COX6C;SLC25A5;NDUFA11;ERN1;UQCRB;NDUFA4;TUBA1A;UQCRQ;UQCRH;COX4I1;COX8A;SLC25A6;COX7C;TUBA4A;NDUFA13;NDUFB7;NDUFA1;TUBA1B;RB1CC1;NDUFB4;COX6A1;PTGS2;CYCS;COX7B;APOE;PSMD13;BRAF;NDUFB11;VDAC1;PIK3CD;NDUFS5;COX5B;NDUFB6;ATP2A3;IL1B;NDUFB3;XBP1;ATG2A;PSMB6;MME;COX5A;DDIT3;CALM2;PSMB7;MAP2K2;NDUFC1;UQCR10;COX7A2;NDUFA6;SDHB;NDUFS6;IL1A;PSMB1;NDUFA2;PPP3CA
27,prerank,MSigDB_Hallmark_2020__Protein Secretion,0.46362741611458474,1.5778199194288638,0.011254019292604502,0.22808768490465156,0.711,17/52,21.45%,CD63;CTSC;STX7;M6PR;CLTC;ATP6V1H;IGF2R;RAB22A;YIPF6;AP3S1;ADAM10;AP2B1;RAB14;PPT1;VPS4B;SNX2;LAMP2
28,prerank,KEGG_2021_Human__Glycerophospholipid metabolism,0.6182958395392882,1.5671116199588127,0.022058823529411766,0.23000275432996872,0.744,9/15,19.91%,ETNK1;CDS2;PISD;LYPLA1;LPCAT2;LYPLA2;LPCAT1;PNPLA6;PCYT1A
29,prerank,MSigDB_Hallmark_2020__Interferon Gamma Response,0.40092149688620893,1.5598783541023231,0.0030816640986132513,0.22455890215647833,0.765,38/133,19.15%,GBP4;SPPL2A;TAP1;PARP14;RNF213;IRF2;CD274;PIM1;P2RY14;STAT1;IFI30;FAS;FCGR1A;TAPBP;SLAMF7;TRIM21;PML;IFIH1;TNFAIP2;UPP1;PTPN6;EPSTI1;DDX60;ARID5B;TRAFD1;GCH1;SAMD9L;APOL6;RIPK2;SAMHD1;OGFR;OAS2;STAT2;ADAR;LCP2;MT2A;PLSCR1;ZBP1
30,prerank,MSigDB_Hallmark_2020__IL-6/JAK/STAT3 Signaling,0.4770805019510958,1.5581786704250755,0.011824324324324325,0.21065763678488683,0.779,21/51,23.43%,IL2RG;CCR1;PIM1;CSF1;STAT1;FAS;CD9;TLR2;STAM2;IL3RA;IFNGR2;LTBR;JUN;IFNGR1;STAT2;IL10RB;IL18R1;CBL;CSF2RA;IL1R1;HMOX1
31,prerank,KEGG_2021_Human__Inflammatory bowel disease,-0.4861244330647098,-1.5483228363271462,0.026004728132387706,0.09310332504020563,0.725,7/28,5.72%,HLA-DPB1;HLA-DRB5;HLA-DPA1;IL18RAP;HLA-DMA;HLA-DRA;HLA-DRB1
32,prerank,KEGG_2021_Human__Thermogenesis,-0.39783241904457656,-1.5391251343068817,0.0026246719160104987,0.09509636980934971,0.736,25/68,17.26%,NDUFB2;COX6C;NDUFA11;UQCRB;NDUFA4;UQCRQ;MAP2K3;UQCRH;COX4I1;ACSL3;COX8A;COX7C;COX14;RPS6;NDUFA13;NDUFB7;NDUFA1;PRKACA;NDUFB4;COX6A1;COX7B;NDUFB11;NDUFS5;COX5B;NDUFB6
33,prerank,MSigDB_Hallmark_2020__Bile Acid Metabolism,0.5663215915113345,1.534036784582522,0.04695652173913043,0.2420500547394149,0.837,4/19,5.94%,HSD17B4;NPC1;GCLM;OPTN
34,prerank,KEGG_2021_Human__Diabetic cardiomyopathy,-0.3906476224000612,-1.520358466775388,0.013927576601671309,0.10395851210685371,0.768,27/77,18.55%,NDUFB2;COX6C;SLC25A5;NDUFA11;UQCRB;NDUFA4;UQCRQ;UQCRH;COX4I1;COX8A;SLC25A6;COX7C;NDUFA13;NDUFB7;MPC2;NDUFA1;NDUFB4;COX6A1;COX7B;NDUFB11;VDAC1;PIK3CD;NDUFS5;COX5B;NDUFB6;ATP2A3;NDUFB3
35,prerank,MSigDB_Hallmark_2020__Estrogen Response Late,-0.4282047270448364,-1.5009657650848875,0.0024937655860349127,0.11315843206153992,0.808,14/46,19.03%,AREG;COX6C;PDCD4;SLC9A3R1;SLC7A5;FABP5;ID2;ELOVL5;FOS;ABHD2;ITPK1;ARL3;TOB1;XBP1
36,prerank,KEGG_2021_Human__Pathways of neurodegeneration,-0.34157538163961665,-1.495938048345947,0.0,0.1119883724891276,0.82,48/155,19.75%,NDUFB2;COX6C;GABARAPL1;SLC25A5;DCTN3;RPS27A;NDUFA11;ERN1;UQCRB;NDUFA4;UBA52;TUBA1A;UQCRQ;MAP2K3;UQCRH;COX4I1;COX8A;SLC25A6;COX7C;TUBA4A;HSPA5;NDUFA13;FUS;NDUFB7;NDUFA1;GPX1;TUBA1B;RB1CC1;NDUFB4;COX6A1;PTGS2;CYCS;COX7B;PSMD13;BRAF;RAB8A;NDUFB11;VDAC1;NDUFS5;COX5B;NDUFB6;ATP2A3;IL1B;NDUFB3;XBP1;ATG2A;PSMB6;COX5A
37,prerank,MSigDB_Hallmark_2020__Oxidative Phosphorylation,-0.3816096190959438,-1.4917048282379146,0.010810810810810811,0.11099068512231218,0.833,36/73,24.75%,NDUFB2;COX6C;SLC25A5;UQCRB;NDUFA4;UQCRQ;ATP1B1;UQCRH;SLC25A3;COX4I1;COX8A;SLC25A6;COX7C;OAT;NDUFB7;PRDX3;NDUFA1;TIMM8B;NDUFB4;COX6A1;MDH2;CYCS;COX7B;POLR2F;VDAC1;COX5B;NDUFB6;NDUFB3;COX5A;ISCU;NDUFC1;UQCR10;COX7A2;NDUFA6;SDHB;MGST3
38,prerank,KEGG_2021_Human__Endocytosis,0.39171356345117236,1.4895175430186234,0.009538950715421303,0.3260024950989128,0.926,44/108,23.96%,IL2RG;CHMP2B;TGFBR1;VPS26A;RAB10;MDM2;CLTC;ARAP2;SH3GLB1;PDCD6IP;IGF2R;ZFYVE16;PML;KIF5B;RAB22A;CHMP5;ARPC5;RAB7A;STAM2;SPG21;HSPA1A;CYTH1;AP2B1;ACTR3;RAB5C;CAPZA2;EPS15;SNX3;RAB5B;CHMP3;VPS4B;HLA-E;USP8;CHMP2A;SNX2;SNX6;CBL;SMAD2;ARAP1;LDLR;RAB11A;CAPZB;SH3GL1;CXCR4
39,prerank,KEGG_2021_Human__Autophagy,0.4391984929932002,1.4843026450136492,0.031932773109243695,0.31839244341472106,0.938,19/54,17.26%,LAMP1;CTSD;RRAGD;SQSTM1;RRAGC;UVRAG;TANK;SH3GLB1;ITPR1;CAMKK2;RAB1A;GABARAPL2;RAB7A;RHEB;ATG12;PIK3CA;PRKCD;TBK1;CFLAR
40,prerank,KEGG_2021_Human__Toxoplasmosis,-0.41194155340455046,-1.470379501019431,0.029411764705882353,0.12369266126926089,0.873,8/51,6.48%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;MAP2K3;HLA-DRB1;GNAI2
41,prerank,KEGG_2021_Human__Cell adhesion molecules,-0.457238371471895,-1.4699861418319542,0.0425531914893617,0.1191771299997991,0.874,7/28,7.23%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1;ICAM3
42,prerank,KEGG_2021_Human__NOD-like receptor signaling pathway,0.39596623252321306,1.4534231081425313,0.024509803921568627,0.3775986245505153,0.96,26/83,17.04%,TRPM7;GBP4;GBP3;HSP90AA1;TANK;TRAF3;CASP5;TRPM2;GBP1;ITPR1;XIAP;STAT1;GABARAPL2;CYBB;GSDMD;CARD16;GBP5;RIPK2;ATG12;AIM2;RNASEL;OAS2;PRKCD;JUN;STAT2;TBK1
43,prerank,KEGG_2021_Human__JAK-STAT signaling pathway,0.43723694668112295,1.4214583634360947,0.06164383561643835,0.44394938513633936,0.977,12/44,18.55%,IL2RG;PIM1;STAT1;LEP;PTPN6;STAM2;IL3RA;IFNGR2;PIK3CA;IFNGR1;STAT2;IL10RB
44,prerank,KEGG_2021_Human__Phagosome,0.3948394093935522,1.4101111335354994,0.0330188679245283,0.4582915138496749,0.981,20/76,11.16%,ATP6V1B2;LAMP1;ATP6V1E1;CANX;ATP6V1D;ATP6V1C1;TAP1;STX7;ATP6V0E1;ATP6AP1;M6PR;ATP6V1H;NCF2;FCGR1A;ITGAM;CYBB;ATP6V0A1;TLR2;RAB7A;TCIRG1
45,prerank,MSigDB_Hallmark_2020__IL-2/STAT5 Signaling,0.4009207969150254,1.4063952565550075,0.03286384976525822,0.44580288718588484,0.983,19/71,19.65%,PLIN2;RRAGD;GBP4;CD48;SPP1;ECM1;PIM1;CSF1;GSTO1;IGF2R;SLC39A8;IL3RA;P2RX4;CST7;IFNGR1;PLSCR1;CAPG;RHOH;BHLHE40
46,prerank,KEGG_2021_Human__Hematopoietic cell lineage,-0.42564403793642247,-1.3847130389888873,0.08470588235294117,0.20430438273217066,0.962,8/32,8.77%,HLA-DPB1;HLA-DRB5;HLA-DPA1;CD55;HLA-DMA;HLA-DRA;HLA-DRB1;ANPEP
47,prerank,KEGG_2021_Human__Osteoclast differentiation,0.3977501332374248,1.3769698759019018,0.06687898089171974,0.5140922168190034,0.994,16/64,17.36%,SQSTM1;TGFBR1;OSCAR;LILRA6;CREB1;SIRPA;NCF2;CSF1;STAT1;FCGR1A;IFNGR2;PIK3CA;JUN;IFNGR1;STAT2;LCP2
48,prerank,KEGG_2021_Human__Th1 and Th2 cell differentiation,-0.42167296352868217,-1.375534591088709,0.06265664160401002,0.20894377495056524,0.972,6/33,5.72%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1
49,prerank,KEGG_2021_Human__B cell receptor signaling pathway,0.44081275089294103,1.3723507094017866,0.09797297297297297,0.5067643103643816,0.994,9/36,20.94%,PIK3AP1;CD22;LILRA6;PTPN6;PIK3CA;JUN;SYK;GSK3B;LYN
50,prerank,KEGG_2021_Human__Complement and coagulation cascades,-0.4896046374608502,-1.3500938084549379,0.11255411255411256,0.23584729964607667,0.982,4/17,1.23%,CFD;C5AR1;CD55;F3
51,prerank,KEGG_2021_Human__Pathways in cancer,0.3309413995792203,1.3154293818713605,0.05752212389380531,0.693668492789784,0.999,21/153,9.78%,ADCY3;PTGER4;IL2RG;EML4;TGFBR1;HSP90AA1;HES1;MDM2;TRAF3;PIM1;TXNRD1;VHL;XIAP;STAT1;E2F3;FAS;EDN1;GSTO1;GNB1;PML;RALGDS
52,prerank,KEGG_2021_Human__Thyroid hormone synthesis,0.5076680036603731,1.3113556925572578,0.125,0.679780787738371,1.0,5/18,8.52%,ADCY3;CANX;CREB1;ITPR1;GSR
53,prerank,KEGG_2021_Human__Leishmaniasis,-0.3634093932664197,-1.2958235522560162,0.0913978494623656,0.31402315661182206,0.998,14/48,18.36%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1;HLA-DQA1;TLR4;FOS;PTGS2;EEF1A1;HLA-DQB1;IL1B;FCGR3B
54,prerank,KEGG_2021_Human__Antigen processing and presentation,-0.3807357089886173,-1.2904899910262748,0.10514018691588785,0.3129064271813579,0.999,9/37,11.54%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1;CD74;HSPA5;HLA-DQA1
55,prerank,KEGG_2021_Human__RNA transport,-0.36562918445867737,-1.288431608432346,0.10714285714285714,0.30677787934186473,0.999,14/47,23.43%,MAGOH;RAN;EIF3I;FUS;PABPC1;EIF4A1;TPR;RBM8A;EEF1A1;EIF4E;NUP98;EIF4EBP2;THOC7;EIF1AY
56,prerank,KEGG_2021_Human__Influenza A,-0.32611823297495673,-1.2771642632345843,0.09859154929577464,0.31819938744984444,0.999,17/82,18.24%,HLA-DPB1;HLA-DRB5;HLA-DPA1;NLRP3;SLC25A5;HLA-DMA;HLA-DRA;HLA-DRB1;SLC25A6;HLA-DQA1;TLR4;CYCS;VDAC1;MX2;PIK3CD;HLA-DQB1;IL1B
57,prerank,KEGG_2021_Human__RIG-I-like receptor signaling pathway,0.4648408582059107,1.2762477779131647,0.17142857142857143,0.7961789342363215,1.0,5/20,17.04%,TANK;TRAF3;IFIH1;ATG12;TBK1
58,prerank,KEGG_2021_Human__Human cytomegalovirus infection,0.34038647924500726,1.2706054427692188,0.08823529411764706,0.7917140781157891,1.0,11/92,9.15%,ADCY3;PTGER4;CCR1;TAP1;MDM2;CREB1;ITPR1;E2F3;FAS;TAPBP;GNB1
59,prerank,KEGG_2021_Human__Renin secretion,0.4807836103537862,1.2644016652211816,0.19454545454545455,0.7870650903978298,1.0,4/17,8.18%,PTGER4;CREB1;ITPR1;EDN1
60,prerank,KEGG_2021_Human__Longevity regulating pathway,0.4062915179735289,1.257752407248711,0.16898954703832753,0.7875601497059347,1.0,7/31,14.18%,ADCY3;CREB1;CAMKK2;SIRT1;RHEB;HSPA1A;PIK3CA
61,prerank,MSigDB_Hallmark_2020__Unfolded Protein Response,-0.3636646199375868,-1.256951025536762,0.1488833746898263,0.3444597729402547,1.0,13/41,25.35%,ERN1;RPS14;SLC7A5;HSPA5;FUS;EIF4A1;CNOT2;EIF4E;XBP1;DDIT4;DNAJB9;HSP90B1;NABP1
62,prerank,KEGG_2021_Human__Circadian entrainment,0.46069982738464466,1.2534435977811427,0.17277486910994763,0.779245201851044,1.0,4/20,9.15%,ADCY3;CREB1;ITPR1;GNB1
63,prerank,KEGG_2021_Human__Estrogen signaling pathway,0.37517170148290857,1.2309523711514545,0.17487266553480477,0.8480841204776332,1.0,5/46,5.97%,ADCY3;CTSD;HSP90AA1;CREB1;ITPR1
64,prerank,KEGG_2021_Human__Th17 cell differentiation,-0.3490265408820437,-1.226445861806767,0.1700507614213198,0.39304018206917135,1.0,12/45,18.24%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;HLA-DRB1;RARA;HLA-DQA1;FOS;HLA-DQB1;STAT5A;IL1B
65,prerank,KEGG_2021_Human__AMPK signaling pathway,0.3982510494449988,1.2261190181124741,0.16150081566068517,0.8404918909285333,1.0,8/30,15.38%,RAB10;CREB1;CAMKK2;SIRT1;LEP;RHEB;PIK3CA;RAB14
66,prerank,KEGG_2021_Human__PD-L1 expression and PD-1 checkpoint pathway in cancer,0.3966347998937581,1.2177038656150734,0.1717687074829932,0.8478769381571911,1.0,9/33,16.42%,EML4;CD274;STAT1;TLR2;PTPN6;IFNGR2;PIK3CA;JUN;IFNGR1
67,prerank,KEGG_2021_Human__Cytokine-cytokine receptor interaction,0.3477996917100336,1.2167776998468585,0.1371610845295056,0.8264610100290014,1.0,12/63,14.06%,IL2RG;CCR1;TNFRSF14;CXCL16;TGFBR1;CSF1;GDF15;FAS;LEP;IL3RA;IFNGR2;LTBR
68,prerank,MSigDB_Hallmark_2020__TNF-alpha Signaling via NF-kB,-0.28153257493232736,-1.2108842036224372,0.07947019867549669,0.4151638083630771,1.0,28/143,14.34%,NR4A2;DUSP1;AREG;BTG1;F3;BCL3;NR4A3;PTPRE;PNRC1;CXCL3;JUNB;MAP2K3;PTX3;MAP3K8;ID2;IER2;CXCL2;FOSB;EHD1;KYNU;BCL2A1;GADD45B;KLF2;CEBPD;FOS;PTGS2;MCL1;BTG2
69,prerank,KEGG_2021_Human__Mineral absorption,0.47209168672378327,1.1994799768596776,0.22530329289428075,0.8750248985710841,1.0,3/15,8.05%,TRPM7;SLC11A2;MT1G
70,prerank,KEGG_2021_Human__Cushing syndrome,0.40433520532505796,1.192082494237837,0.23665480427046262,0.8808819410851134,1.0,4/29,7.11%,ADCY3;CREB1;ITPR1;E2F3
71,prerank,KEGG_2021_Human__Measles,0.34498839566704137,1.1912770689850811,0.20408163265306123,0.8593536505673379,1.0,14/58,18.27%,IL2RG;TRAF3;STAT1;FAS;IFIH1;TLR2;HSPA1A;PIK3CA;OAS2;JUN;STAT2;ADAR;TBK1;IRAK1
72,prerank,KEGG_2021_Human__Tight junction,-0.3335055852384192,-1.1863389236743693,0.19387755102040816,0.4587459854735906,1.0,12/46,18.11%,TUBA1A;SLC9A3R1;RAPGEF2;TUBA4A;TUBA1B;PRKACA;RAB8A;YBX3;F11R;ACTN4;ACTN1;CLDN4
73,prerank,KEGG_2021_Human__Oxidative phosphorylation,-0.3155097307913892,-1.1841714095607205,0.17661691542288557,0.4517804566260258,1.0,21/58,17.26%,NDUFB2;COX6C;NDUFA11;UQCRB;NDUFA4;UQCRQ;PPA1;UQCRH;COX4I1;COX8A;COX7C;NDUFA13;NDUFB7;NDUFA1;NDUFB4;COX6A1;COX7B;NDUFB11;NDUFS5;COX5B;NDUFB6
74,prerank,KEGG_2021_Human__Notch signaling pathway,0.42038882670878014,1.1826158804294993,0.24909090909090909,0.8713868029498042,1.0,8/20,19.37%,MAML2;HES1;ADAM17;NOTCH2;CIR1;PSEN1;DTX3L;CTBP2
75,prerank,MSigDB_Hallmark_2020__Complement,0.3199827758207496,1.1725109921179235,0.18808777429467086,0.8916226584997513,1.0,32/84,24.87%,CTSD;CTSC;IRF2;DOCK4;FCER1G;CASP5;PIM1;LTA4H;ITGAM;LGALS3;HSPA1A;PIK3CA;CLU;PRKCD;PSEN1;ADAM9;CR1;LCP2;S100A12;PLSCR1;USP8;LYN;LAMP2;SERPINA1;PLEK;GNG2;CD59;SERPING1;VCPIP1;CTSB;CASP3;PFN1
76,prerank,KEGG_2021_Human__Inflammatory mediator regulation of TRP channels,0.4108506266806329,1.1705495791907616,0.26523297491039427,0.8771506518788642,1.0,3/24,5.97%,ADCY3;PTGER4;ITPR1
77,prerank,KEGG_2021_Human__Herpes simplex virus 1 infection,-0.29427847505823795,-1.1699326750647985,0.16012084592145015,0.47143325900181476,1.0,11/89,7.89%,HLA-DPB1;HLA-DRB5;HLA-DPA1;SRSF2;SRSF5;SRSF9;HLA-DMA;HLA-DRA;HLA-DRB1;CD74;SRSF3
78,prerank,KEGG_2021_Human__Relaxin signaling pathway,0.3726290259061032,1.1696528047099142,0.24319727891156462,0.8582427374799501,1.0,5/37,9.15%,ADCY3;TGFBR1;CREB1;EDN1;GNB1
79,prerank,KEGG_2021_Human__Sphingolipid signaling pathway,0.3723640823057252,1.1674573175267369,0.2508532423208191,0.8452125832967473,1.0,3/37,4.28%,CTSD;ASAH1;FCER1G
80,prerank,KEGG_2021_Human__Hepatitis B,0.32460048669214514,1.1485183547125355,0.21884984025559107,0.9005270259948569,1.0,15/68,18.27%,TGFBR1;CREB1;ATP6AP1;TRAF3;STAT1;E2F3;FAS;IFIH1;TLR2;PIK3CA;EGR2;JUN;STAT2;TBK1;IRAK1
81,prerank,KEGG_2021_Human__Ferroptosis,0.3901260589395827,1.141950196688423,0.2786885245901639,0.9062182672740009,1.0,10/25,24.34%,SLC3A2;SLC11A2;GCLM;CYBB;SLC39A8;SLC7A11;ATG7;HMOX1;MAP1LC3B;ACSL5
82,prerank,MSigDB_Hallmark_2020__Estrogen Response Early,-0.31554203682025983,-1.1393310467846192,0.24040920716112532,0.5314750587620789,1.0,13/48,19.03%,AREG;AQP3;SLC9A3R1;SLC7A5;RARA;ELOVL5;FOS;ABHD2;GAB2;ITPK1;ARL3;TOB1;XBP1
83,prerank,KEGG_2021_Human__Melanogenesis,0.4087518584534704,1.1382368756497432,0.29963235294117646,0.9010304434471249,1.0,3/21,8.18%,ADCY3;CREB1;EDN1
84,prerank,KEGG_2021_Human__RNA degradation,-0.3864696068493819,-1.1370097831382728,0.27802690582959644,0.5239903432724585,1.0,7/20,18.02%,BTG1;LSM3;PABPC1;LSM7;BTG2;CNOT2;TOB1
85,prerank,KEGG_2021_Human__Natural killer cell mediated cytotoxicity,0.3470782931164248,1.1277408310752244,0.2621035058430718,0.9234242262223014,1.0,17/44,29.50%,CD48;FCER1G;FAS;PTPN6;IFNGR2;PIK3CA;IFNGR1;LCP2;HLA-E;SYK;PTK2B;CASP3;KRAS;PRKCB;TNF;BID;SH3BP2
86,prerank,KEGG_2021_Human__Transcriptional misregulation in cancer,-0.3104721027273878,-1.124787743971973,0.25,0.5412687634468779,1.0,16/53,21.73%,NR4A3;DDX5;ETV6;ID2;FUS;RARA;DOT1L;BCL2A1;SPI1;GADD45B;GADD45A;MAX;DDIT3;MEF2C;NFKBIZ;BIRC3
87,prerank,KEGG_2021_Human__Apelin signaling pathway,0.3597853151672774,1.1205996589750933,0.314878892733564,0.9313615336334686,1.0,6/36,9.15%,ADCY3;TGFBR1;SPP1;ITPR1;GABARAPL2;GNB1
88,prerank,KEGG_2021_Human__Endocrine and other factor-regulated calcium reabsorption,-0.4036260206706806,-1.1176126248445988,0.31363636363636366,0.5464821102115435,1.0,5/16,13.11%,CLTB;ATP1B1;AP2S1;ATP1B3;PRKACA
89,prerank,MSigDB_Hallmark_2020__PI3K/AKT/mTOR  Signaling,0.3386534396077951,1.1123901368663776,0.28161888701517707,0.9445807437518249,1.0,16/49,27.45%,IL2RG;DUSP3;SQSTM1;CLTC;ACTR3;STAT2;TBK1;GSK3B;MKNK1;YWHAB;SMAD2;CXCR4;PFN1;RALB;PRKCB;DAPP1
90,prerank,KEGG_2021_Human__Vascular smooth muscle contraction,0.38122083778633675,1.1099983569820224,0.3019538188277087,0.9343699875245054,1.0,3/27,8.18%,ADCY3;ITPR1;EDN1
91,prerank,KEGG_2021_Human__PI3K-Akt signaling pathway,0.3077203689301905,1.1072177451815033,0.2650793650793651,0.9260599623916578,1.0,20/80,22.61%,PIK3AP1;IL2RG;SPP1;HSP90AA1;MDM2;CREB1;CSF1;GNB1;TLR2;RHEB;IL3RA;PIK3CA;EIF4B;SYK;GSK3B;HSP90AB1;ITGA5;YWHAE;YWHAB;GNG2
92,prerank,KEGG_2021_Human__Chemical carcinogenesis,0.32708683677650685,1.1046689465733952,0.2978723404255319,0.917782926394582,1.0,9/52,16.04%,ADCY3;HSP90AA1;CREB1;XIAP;CYP1B1;GSTO1;PIK3CA;NOTCH2;JUN
93,prerank,KEGG_2021_Human__Necroptosis,0.31860358014700646,1.1039014278109032,0.28044871794871795,0.9026177571367167,1.0,18/61,20.57%,TRPM7;SQSTM1;CHMP2B;HSP90AA1;XIAP;STAT1;FAS;CYBB;CHMP5;IFNGR2;IFNGR1;STAT2;CFLAR;CHMP3;VPS4B;ZBP1;CHMP2A;HSP90AB1
94,prerank,KEGG_2021_Human__Hepatitis C,0.315440516599068,1.0981071662160538,0.31061806656101426,0.9070164374922884,1.0,28/62,34.91%,TRAF3;STAT1;E2F3;FAS;RNASEL;PIK3CA;OAS2;STAT2;TBK1;CFLAR;GSK3B;YWHAE;YWHAB;LDLR;CTNNB1;CASP3;OAS3;KRAS;MX1;PPP2R2A;TNF;BID;RSAD2;RB1;YWHAH;RELA;PPP2CA;GRB2
95,prerank,KEGG_2021_Human__Cellular senescence,0.33059116921249215,1.097715494847834,0.31746031746031744,0.8913555919470851,1.0,8/54,7.92%,TRPM7;SQSTM1;TGFBR1;MDM2;ITPR1;NBN;E2F3;SIRT1
96,prerank,KEGG_2021_Human__Vasopressin-regulated water reabsorption,0.41816909644827027,1.0958779255472901,0.3616636528028933,0.8817798372244995,1.0,2/18,4.34%,ADCY3;CREB1
97,prerank,KEGG_2021_Human__Cholinergic synapse,0.3887990085706678,1.0947133956415744,0.3418181818181818,0.86967482704428,1.0,4/25,9.15%,ADCY3;CREB1;ITPR1;GNB1
98,prerank,KEGG_2021_Human__Mitophagy,-0.3288872894630805,-1.0939716229589256,0.32532751091703055,0.5944186709086161,1.0,6/32,6.45%,GABARAPL1;RPS27A;UBA52;TOMM7;FOXO3;FIS1
99,prerank,MSigDB_Hallmark_2020__Epithelial Mesenchymal Transition,-0.32346614777286126,-1.087194718825131,0.3119047619047619,0.5979396999506689,1.0,14/37,22.36%,AREG;PTX3;ID2;ANPEP;EMP3;QSOX1;IL32;GADD45B;GLIPR1;GADD45A;SAT1;TIMP1;BASP1;LGALS1
100,prerank,KEGG_2021_Human__Spinocerebellar ataxia,-0.3116233510897397,-1.0836859381041377,0.32575757575757575,0.5940227326921549,1.0,12/45,19.25%,SLC25A5;ERN1;SLC25A6;RB1CC1;CYCS;PSMD13;VDAC1;PIK3CD;ATP2A3;XBP1;ATG2A;PSMB6
101,prerank,KEGG_2021_Human__Glutamatergic synapse,0.3937502663188749,1.0828645927244815,0.370304114490161,0.896841663059806,1.0,3/20,9.15%,ADCY3;ITPR1;GNB1
102,prerank,MSigDB_Hallmark_2020__Androgen Response,-0.3000230875676777,-1.0710954506159405,0.31007751937984496,0.6142235904046943,1.0,17/44,25.28%,ELL2;SMS;ACSL3;VAPA;ELOVL5;PA2G4;ABHD2;SLC38A2;XRCC6;ACTN1;SAT1;NCOA4;IDI1;TNFAIP8;DNAJB9;GNAI3;CCND3
103,prerank,MSigDB_Hallmark_2020__Apoptosis,0.29564509104788345,1.0703837933931473,0.3317757009345794,0.9253815343920307,1.0,18/83,17.61%,SQSTM1;TAP1;DPYD;XIAP;FAS;GSR;IGF2R;LGALS3;GCH1;RNASEL;CLU;TSPO;PSEN1;JUN;IFNGR1;PPT1;CFLAR;SLC20A1
104,prerank,MSigDB_Hallmark_2020__mTORC1 Signaling,0.29037079146898015,1.0642870650256275,0.33548387096774196,0.9304076352484958,1.0,23/90,22.17%,CTSC;SQSTM1;CANX;ATP6V1D;M6PR;TXNRD1;IFI30;RAB1A;CD9;LTA4H;GSR;GTF2H1;TES;HSPA4;ACTR3;TBK1;SSR1;SLC7A11;CACYBP;BHLHE40;GSK3B;INSIG1;LDLR
105,prerank,MSigDB_Hallmark_2020__Coagulation,-0.3238248431895824,-1.0625944593156647,0.37199124726477023,0.6240933228867416,1.0,12/33,25.13%,CFD;F3;APOC1;THBD;OLR1;SH2B2;CPQ;ISCU;S100A13;TIMP1;WDR1;FURIN
106,prerank,KEGG_2021_Human__Human T-cell leukemia virus 1 infection,-0.26927477338408295,-1.0556919543927852,0.33724340175953077,0.6304982917690449,1.0,18/78,18.08%,HLA-DPB1;HLA-DRB5;HLA-DPA1;SLC25A5;HLA-DMA;HLA-DRA;RAN;HLA-DRB1;SLC25A6;HLA-DQA1;ANAPC11;SPI1;PRKACA;FOS;VDAC1;PIK3CD;HLA-DQB1;STAT5A
107,prerank,KEGG_2021_Human__Rheumatoid arthritis,0.3237538617681781,1.0444802850197243,0.38209982788296043,0.9892009944147242,1.0,11/45,11.16%,ATP6V1B2;ATP6V1E1;ATP6V1D;ATP6V1C1;ATP6V0E1;ATP6AP1;ATP6V1H;CSF1;ATP6V0A1;TLR2;TCIRG1
108,prerank,KEGG_2021_Human__AGE-RAGE signaling pathway in diabetic complications,0.3353755726900422,1.0438047712343812,0.3902027027027027,0.9753698093031544,1.0,9/39,16.04%,TGFBR1;PIM1;STAT1;EDN1;CYBB;PIK3CA;DIAPH1;PRKCD;JUN
109,prerank,KEGG_2021_Human__Viral protein interaction with cytokine and cytokine receptor,0.34086089823304255,1.0396700380622865,0.41337907375643224,0.9748065129677945,1.0,4/31,5.85%,IL2RG;CCR1;TNFRSF14;CSF1
110,prerank,KEGG_2021_Human__Prostate cancer,0.3290897312916854,1.0369407158945148,0.3908450704225352,0.9684490718117063,1.0,9/37,22.74%,HSP90AA1;MDM2;CREB1;E2F3;PIK3CA;GSK3B;HSP90AB1;PLAU;CTNNB1
111,prerank,MSigDB_Hallmark_2020__p53 Pathway,0.2930839348336458,1.035971556284115,0.37898089171974525,0.9569128667328632,1.0,18/71,18.27%,CTSD;SLC3A2;DRAM1;TAP1;MDM2;RHBDF2;RAP2B;IFI30;FAS;RALGDS;UPP1;TRAFD1;RNF19B;STOM;JUN;CD82;SLC7A11;IRAK1
112,prerank,KEGG_2021_Human__Thyroid cancer,-0.38532269867636204,-1.0301613669546548,0.41014799154334036,0.6863828675894489,1.0,8/15,31.57%,GADD45B;TPR;BRAF;GADD45A;NCOA4;MAP2K2;TCF7L2;RXRA
113,prerank,KEGG_2021_Human__Oocyte meiosis,0.3378635966353649,1.0291061284277006,0.41818181818181815,0.9663384423453929,1.0,3/32,5.97%,ADCY3;SLK;ITPR1
114,prerank,KEGG_2021_Human__Ubiquitin mediated proteolysis,0.3108047696661177,1.0282748580813255,0.4278523489932886,0.9546467789918155,1.0,8/48,9.69%,HERC4;MDM2;VHL;XIAP;UBE2E1;UBE2Z;UBC;PML
115,prerank,KEGG_2021_Human__Phospholipase D signaling pathway,0.34070740262367527,1.0277161681423144,0.39824561403508774,0.9419322434827693,1.0,6/31,14.34%,ADCY3;FCER1G;RALGDS;RHEB;PIK3CA;CYTH1
116,prerank,MSigDB_Hallmark_2020__TGF-beta Signaling,0.3586736938114942,1.025312700816796,0.42538593481989706,0.9366835400612338,1.0,6/22,17.61%,TGFBR1;TRIM33;XIAP;TGIF1;IFNGR2;SLC20A1
117,prerank,MSigDB_Hallmark_2020__G2-M Checkpoint,-0.2847793572935452,-1.020638850079109,0.40694789081885857,0.6994890387599281,1.0,11/50,16.13%,SRSF2;BCL3;TLE3;SLC7A5;TFDP1;UBE2S;PDS5B;HNRNPD;FOXN3;HMGN2;SYNCRIP
118,prerank,KEGG_2021_Human__Platelet activation,0.31819185272027645,1.020277889811677,0.42454394693200664,0.9406942245798694,1.0,9/42,20.94%,ADCY3;FCER1G;ITPR1;FERMT3;PIK3CA;TLN1;LCP2;SYK;LYN
119,prerank,"KEGG_2021_Human__Parathyroid hormone synthesis, secretion and action",0.32557376009086675,1.014694689819655,0.42327150084317033,0.9451775627067949,1.0,4/36,5.97%,ADCY3;MAFB;CREB1;ITPR1
120,prerank,KEGG_2021_Human__Oxytocin signaling pathway,0.3230511653636685,1.0140897024176796,0.426890756302521,0.9337373017287471,1.0,4/38,7.01%,ADCY3;TRPM2;ITPR1;CAMKK2
121,prerank,KEGG_2021_Human__Morphine addiction,0.39369302665908235,1.014007134461599,0.4438305709023941,0.9208571693931187,1.0,2/15,9.15%,ADCY3;GNB1
122,prerank,MSigDB_Hallmark_2020__Inflammatory Response,0.26995624756707204,1.0130673247065993,0.4234930448222566,0.9109932869957822,1.0,21/99,17.36%,C3AR1;PTGER4;SLC11A2;CD48;CSF1;PTAFR;IRAK2;EDN1;CYBB;TAPBP;TLR2;CCRL2;GCH1;RNF144B;P2RX4;RIPK2;IFNGR2;PSEN1;SCARF1;CD82;LCP2
123,prerank,KEGG_2021_Human__Neutrophil extracellular trap formation,-0.28408923917343243,-1.011213381171056,0.4438356164383562,0.7121602346465236,1.0,6/51,8.21%,C5AR1;CLEC7A;SLC25A5;HMGB1;SLC25A6;CAMP
124,prerank,MSigDB_Hallmark_2020__Fatty Acid Metabolism,0.3233563562181661,1.0104787616043889,0.4467005076142132,0.9067902334699697,1.0,4/37,6.70%,HSD17B4;MGLL;HSP90AA1;NBN
125,prerank,KEGG_2021_Human__Retrograde endocannabinoid signaling,-0.2957667297774499,-1.0066623349992299,0.44711538461538464,0.7110297284378897,1.0,24/40,30.41%,NDUFB2;NDUFA11;NDUFA4;GNAI2;NDUFA13;NDUFB7;NDUFA1;PRKACA;NDUFB4;PTGS2;NDUFB11;NDUFS5;NDUFB6;NDUFB3;NDUFC1;GNAI3;NDUFA6;NDUFS6;NDUFA2;NDUFB10;NDUFB1;GNG10;GNB2;NDUFAB1
126,prerank,MSigDB_Hallmark_2020__Xenobiotic Metabolism,0.31199681474870955,1.0044356885946524,0.46153846153846156,0.914289980588323,1.0,16/43,24.59%,NPC1;FAS;PDLIM5;GSR;GSTO1;UPP1;GCH1;PGD;VNN1;TMBIM6;CYP27A1;MT2A;MAN1A1;IL1R1;HMOX1;DHRS7
127,prerank,KEGG_2021_Human__Progesterone-mediated oocyte maturation,0.3581838256463911,0.9918628401906197,0.46,0.9416503297094992,1.0,2/22,3.55%,ADCY3;HSP90AA1
128,prerank,KEGG_2021_Human__Pancreatic secretion,0.37273029759197124,0.9913748744833187,0.45901639344262296,0.931089307656952,1.0,3/19,9.21%,ADCY3;ITPR1;BST1
129,prerank,KEGG_2021_Human__Pancreatic cancer,0.3282556526918867,0.9903271646014888,0.47128378378378377,0.9228301550525754,1.0,5/29,14.18%,TGFBR1;STAT1;E2F3;RALGDS;PIK3CA
130,prerank,MSigDB_Hallmark_2020__Hypoxia,0.27675527924659266,0.9827162768804801,0.5,0.9346338922172106,1.0,12/73,14.21%,PLIN2;RRAGD;PIM1;NAGK;VHL;HEXA;WSB1;TPST2;NR3C1;TES;PLAC8;UGP2
131,prerank,KEGG_2021_Human__PPAR signaling pathway,0.3684937224128745,0.9784494876704143,0.4810344827586207,0.9363388822588542,1.0,4/17,17.08%,PLIN2;UBC;GK;CYP27A1
132,prerank,KEGG_2021_Human__Endometrial cancer,-0.32713993678429976,-0.9748613987823339,0.505800464037123,0.789133996885368,1.0,6/23,16.92%,FOXO3;CTNNA1;GADD45B;BRAF;PIK3CD;GADD45A
133,prerank,MSigDB_Hallmark_2020__Allograft Rejection,-0.2479575376544876,-0.9743004886042465,0.48467966573816157,0.7763542344310169,1.0,11/79,6.76%,NLRP3;BCL3;RPS9;RPL39;IL18RAP;GPR65;HLA-DMA;HLA-DRA;RPL9;RPS3A;CD74
134,prerank,KEGG_2021_Human__Calcium signaling pathway,0.3189233487179106,0.9733522384841522,0.5057851239669422,0.940353769381572,1.0,6/33,12.99%,ADCY3;ITPR1;PTAFR;MCOLN1;ASPH;P2RX4
135,prerank,"KEGG_2021_Human__Growth hormone synthesis, secretion and action",0.30903721460386957,0.9688961218169446,0.5017064846416383,0.9427249384476261,1.0,4/38,6.92%,ADCY3;CREB1;ITPR1;STAT1
136,prerank,MSigDB_Hallmark_2020__heme Metabolism,0.283877600911768,0.9659354845872546,0.5203915171288744,0.9403567035135687,1.0,16/58,17.96%,SLC11A2;SDCBP;BACH1;MARK3;GCLM;OPTN;NR3C1;ATP6V0A1;MPP1;CAST;RNF19A;BMP2K;CIR1;RIOK3;HTATIP2;SLC7A11
137,prerank,KEGG_2021_Human__Proteoglycans in cancer,0.2727296527290065,0.9632532770672771,0.511326860841424,0.9369890898471804,1.0,22/65,29.06%,HPSE;CD63;MDM2;ITPR1;FAS;TLR2;PTPN6;PIK3CA;EIF4B;ITGA5;PLAU;CBL;SMAD2;CTNNB1;CASP3;KRAS;PRKCB;CTSL;RHOA;TNF;PDPK1;ITPR2
138,prerank,KEGG_2021_Human__GABAergic synapse,0.36708276755539704,0.9625027602529319,0.5220588235294118,0.9281004150011456,1.0,3/16,9.15%,ADCY3;GABARAPL2;GNB1
139,prerank,KEGG_2021_Human__GnRH signaling pathway,0.32231760670771037,0.9407207779095019,0.5371329879101899,0.9831276798725194,1.0,2/27,5.97%,ADCY3;ITPR1
140,prerank,KEGG_2021_Human__Aldosterone synthesis and secretion,0.3418513788530373,0.9391647656891404,0.5454545454545454,0.9762965603279272,1.0,3/22,5.97%,ADCY3;CREB1;ITPR1
141,prerank,KEGG_2021_Human__Adrenergic signaling in cardiomyocytes,0.3133884167000102,0.9375632170130019,0.5328836424957841,0.9696470602695445,1.0,2/31,4.34%,ADCY3;CREB1
142,prerank,KEGG_2021_Human__Tuberculosis,0.2543529208321756,0.9270636973787884,0.6003159557661928,0.9890191344923123,1.0,22/88,18.55%,LAMP1;CTSD;FCER1G;CREB1;ATP6AP1;ATP6V1H;STAT1;IRAK2;FCGR1A;ITGAM;ATP6V0A1;TLR2;RAB7A;TCIRG1;RIPK2;IFNGR2;RAB5C;IFNGR1;CR1;RAB5B;IRAK1;IL10RB
143,prerank,KEGG_2021_Human__Salivary secretion,-0.31928887415887486,-0.9170825522341264,0.5537383177570093,0.9306532850800283,1.0,6/20,13.11%,CST3;ATP1B1;CAMP;LYZ;ATP1B3;PRKACA
144,prerank,KEGG_2021_Human__Serotonergic synapse,-0.3083396117123932,-0.9162849754352982,0.5787139689578714,0.9162016558764371,1.0,5/21,14.91%,DUSP1;GNAI2;PRKACA;PTGS2;BRAF
145,prerank,KEGG_2021_Human__TGF-beta signaling pathway,0.3306274381628722,0.9139271215276956,0.5604982206405694,1.0,1.0,4/20,12.36%,TGFBR1;ZFYVE16;TGIF1;HAMP
146,prerank,KEGG_2021_Human__Epstein-Barr virus infection,-0.2270601610734418,-0.9095335054834286,0.6657458563535912,0.9193490692627048,1.0,7/92,5.72%,HLA-DPB1;HLA-DRB5;HLA-DPA1;HLA-DMA;HLA-DRA;MAP2K3;HLA-DRB1
147,prerank,KEGG_2021_Human__Gastric acid secretion,0.32813969430952905,0.9078763251942296,0.6065292096219931,1.0,1.0,2/21,5.97%,ADCY3;ITPR1
148,prerank,KEGG_2021_Human__Glucagon signaling pathway,0.3222467618629849,0.9049056934172309,0.5757575757575758,1.0,1.0,3/23,7.92%,CREB1;ITPR1;SIRT1
149,prerank,KEGG_2021_Human__Glutathione metabolism,0.34694879703868264,0.9022865277452139,0.5985790408525755,1.0,1.0,4/16,12.89%,GCLM;GSR;GSTO1;PGD
150,prerank,KEGG_2021_Human__Viral carcinogenesis,0.24788350064342582,0.8961287669887068,0.6533742331288344,1.0,1.0,16/79,21.73%,GTF2A1;MDM2;CREB1;TRAF3;UBR4;GTF2H1;SP100;LTBR;PIK3CA;EGR2;JUN;HLA-E;SYK;YWHAE;LYN;YWHAB
151,prerank,KEGG_2021_Human__Rap1 signaling pathway,0.2653077445923565,0.8950590914561226,0.6510500807754442,1.0,1.0,16/54,28.30%,ADCY3;DOCK4;CSF1;ITGAM;RALGDS;PIK3CA;TLN1;LCP2;SIPA1L2;CTNNB1;SIPA1;PFN1;RALB;KRAS;PRKCB;RHOA
152,prerank,KEGG_2021_Human__ErbB signaling pathway,-0.293185432033924,-0.8946520432045364,0.6073903002309469,0.9450935988066097,1.0,6/25,22.01%,AREG;ABL2;BRAF;PIK3CD;STAT5A;MAP2K2
153,prerank,KEGG_2021_Human__Kaposi sarcoma-associated herpesvirus infection,0.2424754338279261,0.8943671048495518,0.6676970633693973,1.0,1.0,24/87,24.97%,CCR1;CREB1;TRAF3;ITPR1;STAT1;E2F3;GABARAPL2;FAS;GNB1;UBC;PIK3CA;JUN;IFNGR1;STAT2;TBK1;HLA-E;SYK;GSK3B;LYN;GNG2;CTNNB1;CASP3;GNG5;BECN1
154,prerank,KEGG_2021_Human__Central carbon metabolism in cancer,-0.3202116192935696,-0.8940009019611038,0.5820224719101124,0.9309292243405588,1.0,10/17,39.91%,SLC7A5;PGAM1;PIK3CD;MAP2K2;SCO2;LDHB;LDHA;GLS;RAF1;PTEN
155,prerank,KEGG_2021_Human__Shigellosis,0.23748655055644602,0.8916861712738199,0.6791862284820032,1.0,1.0,24/96,20.66%,RRAGD;SQSTM1;RRAGC;MDM2;ITPR1;GABARAPL2;TIFA;UBC;ARPC5;CAST;RIPK2;ATG12;PIK3CA;CYTH1;TLN1;ACTR3;DIAPH1;PRKCD;JUN;TBK1;CBX3;CALCOCO2;GSK3B;ITGA5
156,prerank,KEGG_2021_Human__Chemokine signaling pathway,0.25093812332736937,0.8912440991539631,0.6731391585760518,0.9944089941150209,1.0,6/72,9.15%,ADCY3;CCR1;CXCL16;FGR;STAT1;GNB1
157,prerank,KEGG_2021_Human__Toll-like receptor signaling pathway,0.27595372834911486,0.8839394719389647,0.6760797342192691,1.0,1.0,9/43,18.27%,SPP1;TRAF3;STAT1;TLR2;PIK3CA;TOLLIP;JUN;TBK1;IRAK1
158,prerank,KEGG_2021_Human__Renal cell carcinoma,0.2933164250873031,0.8835560249901926,0.6441281138790036,0.9944535355335569,1.0,5/31,16.04%,FLCN;VHL;PIK3CA;PAK2;JUN
159,prerank,MSigDB_Hallmark_2020__UV Response Up,-0.2340277126358334,-0.8787477429120684,0.7123287671232876,0.9560963997790802,1.0,11/58,14.34%,BTG1;CLTB;AQP3;JUNB;AP2S1;CXCL2;TUBA4A;FOSB;PRKACA;FOS;BTG2
160,prerank,KEGG_2021_Human__Hepatocellular carcinoma,0.26844480683528,0.8646528400492937,0.6789297658862876,1.0,1.0,11/41,27.42%,TGFBR1;TXNRD1;E2F3;GSTO1;PIK3CA;GSK3B;SMAD2;CTNNB1;HMOX1;KRAS;PRKCB
161,prerank,KEGG_2021_Human__Gap junction,0.3130105400817932,0.8629786404897365,0.6392857142857142,1.0,1.0,2/21,5.97%,ADCY3;ITPR1
162,prerank,KEGG_2021_Human__Chagas disease,0.27019175963159736,0.8618952888296011,0.6899488926746167,1.0,1.0,9/41,18.27%,TGFBR1;FAS;TLR2;IFNGR2;PIK3CA;JUN;IFNGR1;CFLAR;IRAK1
163,prerank,KEGG_2021_Human__Purine metabolism,0.3171849186130937,0.856292143583563,0.6726618705035972,1.0,1.0,1/19,0.28%,ADCY3
164,prerank,MSigDB_Hallmark_2020__Cholesterol Homeostasis,0.32033437971366285,0.8527579776431202,0.640625,1.0,1.0,7/19,22.74%,CXCL16;CD9;LGALS3;CLU;PLSCR1;LDLR;CTNNB1
165,prerank,MSigDB_Hallmark_2020__Adipogenesis,-0.22555806663560846,-0.8417757775046042,0.7821522309711286,1.0,1.0,23/57,25.35%,PDCD4;CHCHD10;UQCRQ;COX8A;PPP1R15B;ATP1B3;NDUFB7;PRDX3;COX6A1;MDH2;COX7B;APOE;CD302;GADD45A;TOB1;STAT5A;BAZ2A;PFKFB3;DNAJB9;UQCR10;SDHB;MGST3;NABP1
166,prerank,KEGG_2021_Human__cGMP-PKG signaling pathway,-0.2413865153442305,-0.8349990886291168,0.7397959183673469,1.0,1.0,17/41,28.90%,SLC25A5;ATP1B1;RGS2;GNAI2;SLC25A6;ATP1B3;VDAC1;ATP2A3;MEF2C;CALM2;MAP2K2;GNAI3;MEF2D;CREB5;PPP3CA;IRS2;VDAC2
167,prerank,MSigDB_Hallmark_2020__Glycolysis,0.2555151271693634,0.8293073651275045,0.7398648648648649,1.0,1.0,5/44,14.21%,RRAGD;SLC25A13;GNPDA1;DSC2;UGP2
168,prerank,KEGG_2021_Human__Fluid shear stress and atherosclerosis,0.24387425355771317,0.8216800684057236,0.7606299212598425,1.0,1.0,14/52,23.43%,SQSTM1;HSP90AA1;NCF2;EDN1;GSTO1;PIK3CA;MEF2A;JUN;HSP90AB1;TXN;CTNNB1;IL1R1;CYBA;HMOX1
169,prerank,KEGG_2021_Human__MicroRNAs in cancer,0.2366354845567451,0.8138569797547568,0.8210180623973727,1.0,1.0,17/56,28.30%,MDM2;PIM1;E2F3;CYP1B1;SIRT1;PIK3CA;NOTCH2;ZEB2;ITGA5;PLAU;MARCKS;HMOX1;CASP3;UBE2I;KRAS;PRKCB;RHOA
170,prerank,KEGG_2021_Human__Apoptosis,0.2366018027531937,0.811978102514356,0.793918918918919,1.0,1.0,10/56,17.26%,CTSD;CTSC;ITPR1;XIAP;FAS;IL3RA;PIK3CA;PARP4;JUN;CFLAR
171,prerank,KEGG_2021_Human__Chronic myeloid leukemia,0.262557871283442,0.8042208859180555,0.7715827338129496,1.0,1.0,3/32,7.11%,TGFBR1;MDM2;E2F3
172,prerank,KEGG_2021_Human__Cell cycle,0.2630382208052091,0.8020009555019695,0.7670068027210885,1.0,1.0,3/31,7.11%,DBF4;MDM2;E2F3
173,prerank,KEGG_2021_Human__TNF signaling pathway,-0.22162885149887637,-0.7978582748443807,0.8363171355498721,1.0,1.0,10/49,18.24%,BCL3;CXCL3;JUNB;MAP2K3;MAP3K8;CXCL2;FOS;PTGS2;PIK3CD;IL1B
174,prerank,KEGG_2021_Human__C-type lectin receptor signaling pathway,-0.2160238096474983,-0.7907296135654049,0.8544152744630071,1.0,1.0,3/49,1.95%,CLEC7A;NLRP3;BCL3
175,prerank,KEGG_2021_Human__Salmonella infection,0.20507883968615823,0.7838235908566494,0.9014308426073132,1.0,1.0,33/110,26.26%,ARL8B;HSP90AA1;M6PR;CASP5;KIF5B;TLR2;ARPC5;RAB7A;GSDMD;DYNLT3;RIPK2;PIK3CA;CYTH1;ACTR3;RAB5C;JUN;VPS18;BRK1;RAB5B;IRAK1;ARL8A;RHOH;HSP90AB1;KPNA4;TXN;CTNNB1;MLKL;PLEKHM2;CASP3;TAB2;PFN1;CASP1;PLEKHM1
176,prerank,KEGG_2021_Human__Pathogenic Escherichia coli infection,-0.19804419046723035,-0.7694311484397134,0.9175531914893617,1.0,1.0,18/77,24.84%,NLRP3;TUBA1A;SLC9A3R1;RPS3;TUBA4A;CYTH4;TLR4;TUBA1B;FOS;CYCS;WASF2;CLDN4;IL1B;ARF6;ARHGEF2;CLDN7;NAIP;MYO1F
177,prerank,KEGG_2021_Human__Colorectal cancer,-0.2321984857774213,-0.7650138782805231,0.8471910112359551,1.0,1.0,7/34,16.92%,AREG;GADD45B;FOS;CYCS;BRAF;PIK3CD;GADD45A
178,prerank,KEGG_2021_Human__Fc epsilon RI signaling pathway,0.2692176816959302,0.7636972692050702,0.8014184397163121,1.0,1.0,9/24,28.77%,FCER1G;ALOX5;PIK3CA;LCP2;SYK;LYN;KRAS;TNF;PDPK1
179,prerank,MSigDB_Hallmark_2020__Pperoxisome,0.26750814063114275,0.7558915346328965,0.8214904679376083,1.0,1.0,1/24,0.47%,HSD17B4
180,prerank,KEGG_2021_Human__Small cell lung cancer,0.25333566396645435,0.7540928770034162,0.8333333333333334,1.0,1.0,3/27,7.11%,TRAF3;XIAP;E2F3
181,prerank,KEGG_2021_Human__Yersinia infection,-0.19981084280032696,-0.7539849706845865,0.9263959390862944,1.0,1.0,12/61,22.39%,NLRP3;MAP2K3;MEFV;PKN2;TLR4;FOS;WASF2;PIK3CD;IL1B;ARF6;MAP2K2;PXN
182,prerank,KEGG_2021_Human__Melanoma,0.2810797046704933,0.7437506313954405,0.8053435114503816,1.0,1.0,3/17,14.18%,MDM2;E2F3;PIK3CA
183,prerank,MSigDB_Hallmark_2020__UV Response Dn,0.23851792916748138,0.7423859712894108,0.8672131147540983,1.0,1.0,10/36,22.17%,MGLL;PDLIM5;NR3C1;SYNE1;NOTCH2;PRDM2;DYRK1A;BHLHE40;INSIG1;LDLR
184,prerank,KEGG_2021_Human__Pertussis,-0.22374316541482092,-0.739456426351789,0.8625,1.0,1.0,8/32,25.88%,NLRP3;GNAI2;TLR4;FOS;IL1B;CALM2;GNAI3;IL1A
185,prerank,KEGG_2021_Human__Phosphatidylinositol signaling system,0.2775579687613471,0.7336519165521282,0.8431372549019608,1.0,1.0,7/18,29.06%,ITPR1;CDS2;PIK3CA;PIP4K2A;PRKCB;MTMR3;ITPR2
186,prerank,KEGG_2021_Human__Amoebiasis,-0.21776752782594558,-0.7312051280772351,0.8786407766990292,1.0,1.0,8/35,18.24%,CXCL3;CXCL2;TLR4;PRKACA;PIK3CD;ACTN4;ACTN1;IL1B
187,prerank,KEGG_2021_Human__Dopaminergic synapse,0.2420576433889951,0.731058092665313,0.8678260869565217,1.0,1.0,4/32,9.75%,CREB1;ITPR1;GNB1;KIF5B
188,prerank,KEGG_2021_Human__Acute myeloid leukemia,0.2431391507355971,0.722125985375552,0.8614035087719298,1.0,1.0,5/27,14.18%,PIM1;FCGR1A;ITGAM;PML;PIK3CA
189,prerank,MSigDB_Hallmark_2020__Reactive Oxygen Species Pathway,0.24886054129358826,0.7205311770778305,0.8546712802768166,1.0,1.0,3/25,8.52%,GCLM;TXNRD1;GSR
190,prerank,KEGG_2021_Human__Ras signaling pathway,0.21119310425107135,0.7176741330608364,0.9290322580645162,1.0,1.0,17/53,28.30%,CSF1;GNB1;RALGDS;PIK3CA;RAB5C;PAK2;TBK1;RAB5B;RASGRP4;STK4;RGL2;GNG2;GNG5;RALB;KRAS;PRKCB;RHOA
191,prerank,MSigDB_Hallmark_2020__DNA Repair,-0.19521328423630357,-0.7110482627064159,0.9362745098039216,1.0,1.0,15/50,26.26%,APRT;VPS28;ARL6IP1;MPC2;RBX1;EDF1;POLR2F;POLR2I;CDA;ELL;TAF13;GUK1;NT5C3A;GTF2A2;POLR2K
192,prerank,KEGG_2021_Human__cAMP signaling pathway,0.21576119262071863,0.7063411897418701,0.9096989966555183,1.0,1.0,3/46,8.18%,ADCY3;CREB1;EDN1
193,prerank,KEGG_2021_Human__MAPK signaling pathway,-0.176968095329559,-0.7059721346379385,0.9761904761904762,1.0,1.0,22/90,24.40%,DUSP1;AREG;MAP2K3;JUND;MAP3K8;RAPGEF2;PRKACA;GADD45B;FOS;BRAF;GADD45A;IL1B;MAPKAPK2;RASA2;PTPN7;MAX;DDIT3;MEF2C;MAP2K2;IL1RAP;MKNK2;PPM1A
194,prerank,KEGG_2021_Human__NF-kappa B signaling pathway,-0.19600690055203887,-0.7011627914420303,0.9390243902439024,1.0,1.0,9/48,18.24%,CXCL3;TNFSF13B;CXCL2;TLR4;BCL2A1;GADD45B;PTGS2;GADD45A;IL1B
195,prerank,KEGG_2021_Human__Non-small cell lung cancer,0.22661950755981788,0.6882812919354798,0.9089316987740805,1.0,1.0,4/29,14.18%,EML4;E2F3;KIF5B;PIK3CA
196,prerank,KEGG_2021_Human__Focal adhesion,0.20499179053909086,0.6881940843666096,0.9526916802610114,1.0,1.0,16/53,30.25%,SPP1;XIAP;PIK3CA;TLN1;DIAPH1;PAK2;JUN;GSK3B;ITGA5;ILK;CTNNB1;PRKCB;RHOA;PDPK1;MYL12A;RAP1B
197,prerank,MSigDB_Hallmark_2020__Mitotic Spindle,0.20165826865096798,0.6810016849415704,0.9544715447154472,1.0,1.0,13/60,21.57%,TLK1;DOCK4;PDLIM5;KIF5B;RABGAP1;PAFAH1B1;NOTCH2;PCM1;HOOK3;ARL8A;YWHAE;CDK5RAP2;MARCKS
198,prerank,KEGG_2021_Human__Neurotrophin signaling pathway,0.20709009333986866,0.6803744409859558,0.9465776293823038,1.0,1.0,10/48,20.72%,IRAK3;IRAK2;RIPK2;PIK3CA;PRKCD;PSEN1;JUN;IRAK1;GSK3B;YWHAE
199,prerank,KEGG_2021_Human__Lipid and atherosclerosis,0.18217782699421328,0.6787908459701918,0.9696969696969697,1.0,1.0,28/95,28.99%,HSP90AA1;TANK;TRAF3;NCF2;ITPR1;FAS;CYBB;TLR2;HSPA1A;PIK3CA;HSPA4;POU2F2;JUN;TBK1;IRAK1;GSK3B;HSP90AB1;LYN;LDLR;CYBA;CASP3;TAB2;CASP1;KRAS;RHOA;TNF;PDPK1;BID
200,prerank,KEGG_2021_Human__FoxO signaling pathway,0.20681630646876326,0.6769821414373228,0.9436860068259386,1.0,1.0,6/43,14.18%,TGFBR1;MDM2;GABARAPL2;SIRT1;ATG12;PIK3CA
201,prerank,KEGG_2021_Human__VEGF signaling pathway,-0.2212213945687767,-0.6583158308442022,0.9320175438596491,1.0,1.0,6/21,27.01%,PTGS2;PIK3CD;MAPKAPK2;MAP2K2;PXN;PPP3CA
202,prerank,KEGG_2021_Human__HIF-1 signaling pathway,0.2014088769752066,0.656542890522338,0.9449081803005008,1.0,1.0,7/42,16.42%,VHL;EDN1;CYBB;IFNGR2;LTBR;PIK3CA;IFNGR1
203,prerank,KEGG_2021_Human__Insulin resistance,0.21981138571810588,0.6565347490149905,0.9195205479452054,1.0,1.0,10/30,28.77%,CREB1;PPP1R3E;PIK3CA;PRKCD;GSK3B;MLX;CRTC2;PRKCB;TNF;PDPK1
204,prerank,KEGG_2021_Human__Bacterial invasion of epithelial cells,0.21272057882968137,0.6489853261003967,0.9482142857142857,1.0,1.0,8/30,22.74%,CLTC;ARPC5;PIK3CA;ACTR3;ITGA5;CBL;ILK;CTNNB1
205,prerank,KEGG_2021_Human__Insulin signaling pathway,-0.18808366998716136,-0.6466147091828687,0.9748743718592965,1.0,1.0,14/39,28.52%,PPP1R3B;RPS6;PRKACA;BRAF;PIK3CD;PTPN1;EIF4E;SH2B2;CALM2;MAP2K2;MKNK2;SREBF1;RAPGEF1;IRS2
206,prerank,KEGG_2021_Human__IL-17 signaling pathway,-0.18796650986595737,-0.6450041105482126,0.9624724061810155,1.0,1.0,6/37,13.96%,CXCL3;JUND;CXCL2;FOSB;FOS;PTGS2
207,prerank,KEGG_2021_Human__mRNA surveillance pathway,-0.2023022691297278,-0.6381413951638263,0.9511002444987775,1.0,1.0,4/28,14.72%,MAGOH;FUS;PABPC1;RBM8A
208,prerank,KEGG_2021_Human__Human immunodeficiency virus 1 infection,0.17529362152982997,0.6352756090551787,0.9824281150159745,1.0,1.0,25/75,29.06%,TAP1;ITPR1;FAS;TAPBP;GNB1;TLR2;PIK3CA;SAMHD1;PAK2;JUN;TBK1;IRAK1;HLA-E;PTK2B;GNG2;CXCR4;CASP3;TAB2;GNG5;HLA-F;KRAS;PRKCB;TNF;BID;ITPR2
209,prerank,KEGG_2021_Human__Axon guidance,0.20681655201260965,0.6308068147184366,0.9533213644524237,1.0,1.0,12/32,29.81%,PIK3CA;PLXNC1;PAK2;SEMA4A;GSK3B;EPHB1;ILK;CXCR4;KRAS;RHOA;PDPK1;MYL12A
210,prerank,KEGG_2021_Human__Prolactin signaling pathway,-0.2094338347181019,-0.6297415083031435,0.9433962264150944,1.0,1.0,5/22,22.01%,FOXO3;FOS;PIK3CD;STAT5A;MAP2K2
211,prerank,KEGG_2021_Human__Wnt signaling pathway,-0.20193684968556502,-0.6237944143810636,0.9610983981693364,1.0,1.0,15/27,40.13%,TLE3;PRKACA;RBX1;TLE4;TBL1X;CCND3;PPP3CA;TCF7L2;PPP3R1;CSNK1A1;SKP1;CREBBP;FRAT2;RAC2;TBL1XR1
212,prerank,KEGG_2021_Human__Adipocytokine signaling pathway,0.22596625888885113,0.6161513292194885,0.9290657439446367,1.0,1.0,2/19,9.03%,CAMKK2;LEP
213,prerank,MSigDB_Hallmark_2020__Myogenesis,0.2021675231502115,0.6146528365833795,0.9634146341463414,1.0,1.0,8/33,19.65%,ATP6AP1;GABARAPL2;CLU;FLII;MEF2A;KIFC3;SVIL;BHLHE40
214,prerank,KEGG_2021_Human__Alcoholism,0.20870162313001478,0.6098802557246973,0.9576719576719577,1.0,1.0,3/27,9.15%,CREB1;CAMKK2;GNB1
215,prerank,KEGG_2021_Human__Protein processing in endoplasmic reticulum,0.17235469980463888,0.6027253771242747,0.9904458598726115,1.0,1.0,12/68,20.57%,CANX;HSP90AA1;DAD1;UBQLN1;HSPA1A;HSPH1;SEC24B;OS9;DERL2;SSR1;MAN1A1;HSP90AB1
216,prerank,MSigDB_Hallmark_2020__Apical Junction,0.18696898738373627,0.5886430675963026,0.9675324675324676,1.0,1.0,2/39,4.53%,CD274;SIRPA
217,prerank,KEGG_2021_Human__p53 signaling pathway,-0.2029591786651314,-0.587626129819122,0.9594882729211087,1.0,1.0,4/21,16.92%,SIVA1;GADD45B;CYCS;GADD45A
218,prerank,KEGG_2021_Human__Glioma,0.2003779249775678,0.5848374730389877,0.9603603603603603,1.0,1.0,2/25,7.11%,MDM2;E2F3
219,prerank,KEGG_2021_Human__Gastric cancer,0.1938783429438443,0.5844857096291981,0.9755244755244755,1.0,1.0,6/29,22.74%,TGFBR1;E2F3;PIK3CA;GSK3B;SMAD2;CTNNB1
220,prerank,KEGG_2021_Human__Breast cancer,0.19012370537080214,0.5829324640513169,0.9725085910652921,1.0,1.0,5/33,16.04%,HES1;E2F3;PIK3CA;NOTCH2;JUN
221,prerank,KEGG_2021_Human__Legionellosis,-0.17213391377452097,-0.5780001503427918,0.9883720930232558,1.0,1.0,7/35,19.06%,CXCL3;CXCL2;TLR4;CYCS;EEF1A1;IL1B;SAR1A
222,prerank,KEGG_2021_Human__Amphetamine addiction,0.22047687743072186,0.5748257330716413,0.9690346083788707,1.0,1.0,2/18,7.92%,CREB1;SIRT1
223,prerank,KEGG_2021_Human__Choline metabolism in cancer,0.19790154140117738,0.5689026100119283,0.9755671902268761,1.0,1.0,9/25,28.77%,RALGDS;RHEB;PIK3CA;LYPLA1;JUN;PCYT1A;KRAS;PRKCB;PDPK1
224,prerank,KEGG_2021_Human__Long-term potentiation,-0.18457016860288086,-0.5641628454125724,0.9953703703703703,1.0,1.0,14/24,40.06%,PRKACA;BRAF;CALM2;MAP2K2;PPP3CA;CALM1;PPP3R1;PPP1CB;RPS6KA3;RAP1A;CREBBP;GNAQ;RAF1;ATF4
225,prerank,KEGG_2021_Human__Leukocyte transendothelial migration,0.16953286382609886,0.5571786490344268,0.9916107382550335,1.0,1.0,14/46,30.25%,NCF2;ITGAM;CYBB;PIK3CA;RHOH;PTK2B;CTNNB1;CYBA;SIPA1;CXCR4;PRKCB;RHOA;MYL12A;RAP1B
226,prerank,KEGG_2021_Human__Proteasome,-0.18092522179974652,-0.5562477603422782,0.9846153846153847,1.0,1.0,24/24,82.08%,PSMD13;PSMB6;PSMB7;PSMB1;PSMA3;PSMB10;PSME1;PSMA5;PSMB3;PSMB9;PSME2;POMP;PSMC6;PSMB8;PSMC1;PSMA4;PSMB4;PSMD8;ADRM1;PSMA1;PSMA7;PSMA6;PSMD4;PSMD7
227,prerank,KEGG_2021_Human__Fc gamma R-mediated phagocytosis,0.17497065537677406,0.5508521703722166,0.9931153184165232,1.0,1.0,8/43,21.57%,FCGR1A;ARPC5;PIK3CA;ACTR3;PRKCD;SYK;LYN;MARCKS
228,prerank,KEGG_2021_Human__Hippo signaling pathway,0.18117404664389075,0.5502171703054412,0.9831932773109243,1.0,1.0,2/32,4.72%,TGFBR1;STK3
229,prerank,KEGG_2021_Human__Thyroid hormone signaling pathway,-0.16517327840257268,-0.5463939681281286,0.9906976744186047,1.0,1.0,7/35,17.80%,ATP1B1;ATP1B3;PRKACA;NCOA2;NOTCH1;PIK3CD;ATP2A3
230,prerank,KEGG_2021_Human__T cell receptor signaling pathway,0.17832051163876284,0.5413416219251201,0.9879931389365352,1.0,1.0,13/31,34.91%,PTPN6;PIK3CA;PAK2;JUN;LCP2;GSK3B;KRAS;RHOA;TNF;PDPK1;BCL10;RELA;GRB2
231,prerank,KEGG_2021_Human__Signaling pathways regulating pluripotency of stem cells,-0.15983605795172467,-0.5080686945333392,0.995249406175772,1.0,1.0,12/27,38.58%,ID2;PIK3CD;MAP2K2;JARID2;KAT6A;PCGF5;KLF4;JAK3;IGF1R;IL6ST;STAT3;RAF1
232,prerank,KEGG_2021_Human__Adherens junction,0.1748862445211582,0.4921499664483138,0.9944852941176471,1.0,1.0,2/25,10.69%,TGFBR1;PTPN6
233,prerank,KEGG_2021_Human__Long-term depression,-0.16136574799055373,-0.44337012589161495,0.9953703703703703,0.9988508749020633,1.0,4/16,23.65%,GNAI2;BRAF;MAP2K2;GNAI3
234,prerank,KEGG_2021_Human__Cytosolic DNA-sensing pathway,0.15608176369309085,0.4353948271902101,0.9982363315696648,1.0,1.0,4/20,19.15%,AIM2;ADAR;TBK1;ZBP1
235,prerank,KEGG_2021_Human__Regulation of actin cytoskeleton,0.1108163934898285,0.38146884812571324,1.0,0.9996720727143111,1.0,17/63,32.20%,ITGAM;ARPC5;PIK3CA;ACTR3;DIAPH1;PAK2;BRK1;ITGA5;PIP4K2A;CXCR4;PFN1;KRAS;RHOA;ARPC1B;MYL12A;ARHGEF1;EZR
